Acumen Pharmaceuticals - ABOS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.00
  • Forecasted Upside: 354.55%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$2.64
+0 (0.00%)

This chart shows the closing price for ABOS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Acumen Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ABOS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ABOS

Analyst Price Target is $12.00
▲ +354.55% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Acumen Pharmaceuticals in the last 3 months. The average price target is $12.00, with a high forecast of $15.00 and a low forecast of $8.00. The average price target represents a 354.55% upside from the last price of $2.64.

This chart shows the closing price for ABOS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Acumen Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/22/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/22/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/20/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/18/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/17/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/16/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/15/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/14/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00Low
3/27/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00Low
12/12/2023Deutsche Bank AktiengesellschaftInitiated CoverageBuy$8.00Low
8/9/2023HC WainwrightReiterated RatingBuy ➝ Buy$15.00Low
8/9/2023Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$13.00Low
7/20/2023Bank of AmericaInitiated CoverageBuyN/A
5/18/2023Cantor FitzgeraldInitiated CoverageOverweight$13.00Low
3/28/2023HC WainwrightReiterated RatingBuy$15.00Low
3/28/2023Credit Suisse GroupLower TargetOutperform$16.00 ➝ $13.00Low
2/2/2023HC WainwrightReiterated RatingBuy$15.00Low
11/15/2022Credit Suisse GroupLower TargetOutperform$17.00 ➝ $16.00Low
10/5/2022BTIG ResearchBoost TargetBuy$15.00 ➝ $22.00Low
8/16/2022HC WainwrightReiterated RatingBuy$15.00Low
7/15/2022BTIG ResearchInitiated CoverageBuy$15.00Low
6/30/2022HC WainwrightInitiated CoverageBuy$15.00Low
3/29/2022Credit Suisse GroupLower TargetOutperform$26.00 ➝ $17.00High
1/21/2022Bank of AmericaUpgradeNeutral ➝ Buy$16.00 ➝ $14.00High
7/26/2021UBS GroupInitiated CoverageBuy$27.00High
7/26/2021Stifel NicolausInitiated CoverageBuy$27.00High
7/26/2021Credit Suisse GroupInitiated CoverageOutperform$26.00High
7/26/2021Bank of AmericaInitiated CoverageNeutral$20.00High
(Data available from 6/14/2019 forward)

News Sentiment Rating

0.92 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/17/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/17/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/16/2024
  • 4 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/15/2024
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/16/2024
  • 5 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/15/2024
  • 4 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/15/2024
  • 4 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/14/2024

Current Sentiment

  • 4 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Acumen Pharmaceuticals logo
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Read More

Today's Range

Now: $2.64
Low: $2.57
High: $2.66

50 Day Range

MA: $3.28
Low: $2.49
High: $3.89

52 Week Range

Now: $2.64
Low: $1.81
High: $11.31

Volume

205,119 shs

Average Volume

336,167 shs

Market Capitalization

$158.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.15

Frequently Asked Questions

What sell-side analysts currently cover shares of Acumen Pharmaceuticals?

The following Wall Street research analysts have issued reports on Acumen Pharmaceuticals in the last twelve months: Bank of America Co., Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, and HC Wainwright.
View the latest analyst ratings for ABOS.

What is the current price target for Acumen Pharmaceuticals?

3 Wall Street analysts have set twelve-month price targets for Acumen Pharmaceuticals in the last year. Their average twelve-month price target is $12.00, suggesting a possible upside of 354.5%. HC Wainwright has the highest price target set, predicting ABOS will reach $15.00 in the next twelve months. Deutsche Bank Aktiengesellschaft has the lowest price target set, forecasting a price of $8.00 for Acumen Pharmaceuticals in the next year.
View the latest price targets for ABOS.

What is the current consensus analyst rating for Acumen Pharmaceuticals?

Acumen Pharmaceuticals currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ABOS will outperform the market and that investors should add to their positions of Acumen Pharmaceuticals.
View the latest ratings for ABOS.

What other companies compete with Acumen Pharmaceuticals?

How do I contact Acumen Pharmaceuticals' investor relations team?

The company's listed phone number is 434-297-1000 and its investor relations email address is [email protected]. The official website for Acumen Pharmaceuticals is www.acumenpharm.com. Learn More about contacing Acumen Pharmaceuticals investor relations.